Clinical Trials · NCT02847403
Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
- Enrollment
- 40
- Start date
- Feb 2016
- Locations
- 2 sites, Italy
- Primary endpoint
- Improvement of ADAS-cog Alzheimer's Disease Assessment Scale defined by ADAS-cog score at 16 (V2) and at 32 weeks (V3) compared to baseline